TLCD1 inhibitors refers to a class of chemical compounds designed to target and modulate the activity of the TLCD1 protein. TLCD1, an acronym for Targeted Ligand for Cell Differentiation 1, is a molecular target that plays a crucial role in cell signaling pathways and proliferation. These inhibitors have garnered significant attention in the field of molecular biology and pharmacology due to their involvement in regulating cell functions and influencing cellular behavior.
At the core of TLCD1 inhibitors' mechanism of action lies their ability to interfere with the catalytic activity of the TLCD1 protein. Typically, these inhibitors are small organic molecules that possess a specific structural arrangement, allowing them to bind to the active site of TLCD1. This binding event obstructs the enzymatic activity of TLCD1, inhibiting its kinase function. Kinases, including TLCD1, are essential regulators of phosphorylation events within cells, which, in turn, control intracellular signaling cascades. By blocking TLCD1's kinase activity, these inhibitors disrupt the normal flow of cellular signaling pathways, leading to a variety of downstream effects that can influence cell growth, differentiation, and survival.The diversity within the class of TLCD1 inhibitors is notable, as researchers have developed numerous chemical entities with varying degrees of potency and specificity. Their effectiveness in modulating TLCD1 activity makes them valuable tools for elucidating the intricate molecular mechanisms underlying cell signaling. As research in this field progresses, the development of more selective and potent TLCD1 inhibitors may unlock further insights into the fundamental biology of cell differentiation and proliferation, offering new avenues for future research and discovery in various scientific disciplines.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits the tyrosine kinase activity of TLCD1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Blocks TLCD1 kinase activity by binding to its ATP-binding site. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Targets and inhibits TLCD1 through competitive kinase binding. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Potent inhibitor of TLCD1 kinase, binding to its active site. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Selectively inhibits the TLCD1 mutant kinase activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Inhibits TLCD1 and other EGFR family kinases. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Irreversibly inhibits TLCD1 and other ErbB family kinases. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Targets TLCD1 and EGFR kinases, inhibiting their activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual inhibitor of TLCD1 and EGFR, disrupting their signaling. | ||||||